Zhejiang Tailin Bioengineering Co Ltd (300813) - Cash Flow Conversion Efficiency

Latest as of December 2025: 0.053x

Based on the latest financial reports, Zhejiang Tailin Bioengineering Co Ltd (300813) has a cash flow conversion efficiency ratio of 0.053x as of December 2025. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow (CN¥42.25 Million ≈ $6.18 Million USD) by net assets (CN¥804.29 Million ≈ $117.69 Million USD). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations. See net asset quality index of Zhejiang Tailin Bioengineering Co Ltd to measure how much of total assets are equity-financed.

Zhejiang Tailin Bioengineering Co Ltd - Cash Flow Conversion Efficiency Trend (2013–2025)

This chart illustrates how Zhejiang Tailin Bioengineering Co Ltd's cash flow conversion efficiency has evolved over time, based on yearly financial data. Check 300813 operating cash flow to net income to evaluate the quality of earnings relative to operating cash generation.

Zhejiang Tailin Bioengineering Co Ltd Competitors by Cash Flow Conversion Efficiency

The table below lists competitors of Zhejiang Tailin Bioengineering Co Ltd ranked by their cash flow conversion efficiency.

Company	Cash Flow Conversion Efficiency
Hunan Hengguang Technology Co.Ltd. SHE:301118	0.051x
Carlsmed, Inc. Common Stock NASDAQ:CARL	-0.141x
Mia Teknoloji AS IS:MIATK	0.025x
SamsungFN REIT Co. Ltd. KO:448730	N/A
Baader Bank Aktiengesellschaft F:BWB	N/A
Thinkingdom Media Group Ltd SHG:603096	0.015x
Bystronic AG SW:BYS	-0.031x
Sidetrade PA:ALBFR	0.086x

Annual Cash Flow Conversion Efficiency for Zhejiang Tailin Bioengineering Co Ltd (2013–2025)

The table below shows the annual cash flow conversion efficiency of Zhejiang Tailin Bioengineering Co Ltd from 2013 to 2025. For the full company profile with market capitalisation and key ratios, see Zhejiang Tailin Bioengineering Co Ltd (300813) market capitalisation.

Year	Net Assets	Operating Cash Flow	Cash Flow Conversion Efficiency	Change
2025-12-31	CN¥804.29 Million ≈ $117.69 Million	CN¥57.11 Million ≈ $8.36 Million	0.071x	+136.34%
2024-12-31	CN¥820.73 Million ≈ $120.10 Million	CN¥24.66 Million ≈ $3.61 Million	0.030x	+911.17%
2023-12-31	CN¥650.24 Million ≈ $95.15 Million	CN¥1.93 Million ≈ $282.70K	0.003x	-97.85%
2022-12-31	CN¥647.45 Million ≈ $94.74 Million	CN¥89.39 Million ≈ $13.08 Million	0.138x	+90.94%
2021-12-31	CN¥497.38 Million ≈ $72.78 Million	CN¥35.96 Million ≈ $5.26 Million	0.072x	-69.78%
2020-12-31	CN¥444.24 Million ≈ $65.01 Million	CN¥106.28 Million ≈ $15.55 Million	0.239x	+88.75%
2019-12-31	CN¥229.11 Million ≈ $33.53 Million	CN¥29.04 Million ≈ $4.25 Million	0.127x	-33.89%
2018-12-31	CN¥194.70 Million ≈ $28.49 Million	CN¥37.33 Million ≈ $5.46 Million	0.192x	+21.87%
2017-12-31	CN¥146.48 Million ≈ $21.44 Million	CN¥23.04 Million ≈ $3.37 Million	0.157x	-42.03%
2016-12-31	CN¥116.31 Million ≈ $17.02 Million	CN¥31.56 Million ≈ $4.62 Million	0.271x	+7.74%
2015-12-31	CN¥97.42 Million ≈ $14.26 Million	CN¥24.54 Million ≈ $3.59 Million	0.252x	-20.82%
2014-12-31	CN¥55.04 Million ≈ $8.05 Million	CN¥17.51 Million ≈ $2.56 Million	0.318x	+79.38%
2013-12-31	CN¥64.92 Million ≈ $9.50 Million	CN¥11.51 Million ≈ $1.68 Million	0.177x	--

About Zhejiang Tailin Bioengineering Co Ltd

SHE:300813 China Medical Devices

Market Cap

$331.83 Million

CN¥2.27 Billion CNY

Market Cap Rank

#14231 Global

#4220 in China

Share Price

CN¥18.71

Change (1 day)

+3.48%

52-Week Range

CN¥17.08 - CN¥40.33

All Time High

CN¥64.43